Glutathione accelerates osteoclast differentiation and inflammatory bone destruction

Area of Science:

• Biochemistry
• Immunology
• Bone Biology

Background:

• Chronic inflammation leads to bone destruction mediated by osteoclasts.
• Osteoclast differentiation is regulated by various molecules, including receptor activator of NF-κB (RANK) ligand.
• Glutathione (GSH), an endogenous antioxidant, is thought to suppress osteoclastogenesis, but its role in inflammation-driven bone loss is unclear.

Purpose of the Study:

• To investigate the role of glutathione (GSH) in inflammatory cytokine-stimulated osteoclast differentiation and bone destruction.
• To elucidate the molecular mechanisms by which GSH influences osteoclastogenesis under inflammatory conditions.

Main Methods:

• In vitro studies using inflammatory cytokines to stimulate osteoclast differentiation.
• Assessment of osteoclast formation, marker gene expression, and nuclear factor of activated T cells c1 (NFATc1) localization.
• In vivo experiments using a mouse calvarial model of inflammatory bone destruction.

Main Results:

• Glutathione (GSH) significantly promoted TNFα-induced osteoclast formation and bone resorption.
• GSH facilitated the nuclear translocation of NFATc1, a key regulator of osteoclastogenesis.
• In vivo, GSH treatment markedly increased osteolytic lesion size in a mouse model.

Conclusions:

• Glutathione (GSH) accelerates osteoclast differentiation and inflammatory bone destruction, challenging its traditional antioxidant role in this context.
• GSH emerges as a critical mediator in the pathogenesis of inflammatory bone diseases driven by osteoclasts.